<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00982072</url>
  </required_header>
  <id_info>
    <org_study_id>13HH1283</org_study_id>
    <secondary_id>2009-014292-52</secondary_id>
    <nct_id>NCT00982072</nct_id>
  </id_info>
  <brief_title>Tacrolimus Versus Prednisolone for the Treatment of Minimal Change Disease</brief_title>
  <acronym>MinTAC</acronym>
  <official_title>Tacrolimus vs Prednisolone for the Treatment Minimal Change Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College Healthcare NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College Healthcare NHS Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness of tacrolimus (prograf) versus&#xD;
      prednisolone for the treatment of nephrotic syndrome secondary to minimal change disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Minimal change disease is a common cause of nephrotic syndrome in adults. Standard treatment&#xD;
      is with high dose steroids which is often effective in controlling the nephrotic syndrome but&#xD;
      has a high morbidity due to the side effects of the steroids. There is also a high relapse&#xD;
      rate,therefore many patients require long term steroid therapy to control their disease which&#xD;
      has significant morbidity and mortality. Some patients are or also become steroid resistant.&#xD;
      There are studies showing the effectiveness of alkylating agents such as cyclophosphamide but&#xD;
      the use of these drugs is limited by their toxicity, including increased rates of infection,&#xD;
      cancers and infertility.&#xD;
&#xD;
      Tacrolimus (prograf) is a T-cell specific calcineurin inhibitor that shares similar&#xD;
      immunosuppressive actions with cyclosporine A.In other glomerular diseases such as focal&#xD;
      segmental glomerulosclerosis and membranous glomerulonephritis, prograf has been shown to be&#xD;
      a very effective treatment for proteinuria. This may be due to the immunomodulatory effects&#xD;
      on the underlying disease, but there may also be a direct effect of tacrolimus (prograf) on&#xD;
      the podocyte, stabilising the actin cytoskeleton and therefore decreasing protein&#xD;
      leak.Therefore tacrolimus (prograf) is likely to be effective in reducing proteinuria in&#xD;
      minimal change disease.It has also been shown to have a good side effect profile when used to&#xD;
      allow the avoidance of steroids in transplantation.This study aims to prospectively study if&#xD;
      tacrolimus (prograf) is effective as treatment for minimal change disease compared with&#xD;
      standard therapy with steroids, and whether it has advantages in terms of side effect profile&#xD;
      and prevention of relapse.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2009</start_date>
  <completion_date type="Actual">October 10, 2019</completion_date>
  <primary_completion_date type="Actual">October 10, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Complete Remission From Nephrotic Syndrome at 8 Weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>normalisation of serum albumin and urine PCR &lt;50 units</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving Complete Remission From Nephrotic Syndrome at 16 and 26 Weeks</measure>
    <time_frame>16 and 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving Remission Who Then Relapse</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Serious Adverse Events</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Baseline Glomerular Filtration Rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Minimal Change Disease</condition>
  <arm_group>
    <arm_group_label>prednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>prednisolone tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tacrolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tacrolimus tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <description>tacrolimus0.05mg/kg bd (levels 6-12ng/ml)</description>
    <arm_group_label>tacrolimus</arm_group_label>
    <other_name>prograff</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisolone</intervention_name>
    <description>Prednisolone 1mg/kg maximum 60mg od</description>
    <arm_group_label>prednisolone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with nephrotic syndrome (hypoalbuminaemia and protein creatinine ratio (PCR)&#xD;
             &gt; 100units), secondary to minimal change disease.&#xD;
&#xD;
          -  Age over 18.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hepatitis B, hepatitis C or HIV infection.&#xD;
&#xD;
          -  Untreated infection.&#xD;
&#xD;
          -  Females who are pregnant, breast feeding, or at risk of pregnancy and not using a&#xD;
             medically acceptable form of contraception.&#xD;
&#xD;
          -  Patients who have been treated with immunosuppression over the last 18 months.&#xD;
&#xD;
          -  Patients who have had more than 3 relapses of nephrotic syndrome within 5 years.&#xD;
&#xD;
          -  Any condition judged by the investigator that would cause the study to be detrimental&#xD;
             to the patient.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Megan Griffith, MBChBPhDFRCP</last_name>
    <role>Study Chair</role>
    <affiliation>Imperial College NHS Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tom Cairns, MBBSMRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 OHS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 21, 2009</study_first_submitted>
  <study_first_submitted_qc>September 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2009</study_first_posted>
  <results_first_submitted>March 16, 2021</results_first_submitted>
  <results_first_submitted_qc>April 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 4, 2021</results_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nephrotic minimal change tacrolimus prednisolone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephrosis, Lipoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 2, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT00982072/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Prednisolone</title>
          <description>prednisolone tablets&#xD;
prednisolone: Prednisolone 1mg/kg maximum 60mg od</description>
        </group>
        <group group_id="P2">
          <title>Tacrolimus</title>
          <description>tacrolimus tablets&#xD;
tacrolimus: tacrolimus0.05mg/kg bd (levels 6-12ng/ml)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Prednisolone</title>
          <description>prednisolone tablets&#xD;
prednisolone: Prednisolone 1mg/kg maximum 60mg od</description>
        </group>
        <group group_id="B2">
          <title>Tacrolimus</title>
          <description>tacrolimus tablets&#xD;
tacrolimus: tacrolimus0.05mg/kg bd (levels 6-12ng/ml)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>18 years and over</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Complete Remission From Nephrotic Syndrome at 8 Weeks</title>
        <description>normalisation of serum albumin and urine PCR &lt;50 units</description>
        <time_frame>8 weeks</time_frame>
        <population>Patients at 8 weeks of therapy- on intention to treat basis</population>
        <group_list>
          <group group_id="O1">
            <title>Prednisolone</title>
            <description>prednisolone tablets&#xD;
prednisolone: Prednisolone 1mg/kg maximum 60mg od</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus</title>
            <description>tacrolimus tablets&#xD;
tacrolimus: tacrolimus0.05mg/kg bd (levels 6-12ng/ml)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Complete Remission From Nephrotic Syndrome at 8 Weeks</title>
          <description>normalisation of serum albumin and urine PCR &lt;50 units</description>
          <population>Patients at 8 weeks of therapy- on intention to treat basis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving Complete Remission From Nephrotic Syndrome at 16 and 26 Weeks</title>
        <time_frame>16 and 26 weeks</time_frame>
        <population>Patients on intention to treat basis</population>
        <group_list>
          <group group_id="O1">
            <title>Prednisolone</title>
            <description>prednisolone tablets&#xD;
prednisolone: Prednisolone 1mg/kg maximum 60mg od</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus</title>
            <description>tacrolimus tablets&#xD;
tacrolimus: tacrolimus0.05mg/kg bd (levels 6-12ng/ml)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving Complete Remission From Nephrotic Syndrome at 16 and 26 Weeks</title>
          <population>Patients on intention to treat basis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>16 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>26 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving Remission Who Then Relapse</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prednisolone</title>
            <description>prednisolone tablets&#xD;
prednisolone: Prednisolone 1mg/kg maximum 60mg od</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus</title>
            <description>tacrolimus tablets&#xD;
tacrolimus: tacrolimus0.05mg/kg bd (levels 6-12ng/ml)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving Remission Who Then Relapse</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Serious Adverse Events</title>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prednisolone</title>
            <description>prednisolone tablets&#xD;
prednisolone: Prednisolone 1mg/kg maximum 60mg od</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus</title>
            <description>tacrolimus tablets&#xD;
tacrolimus: tacrolimus0.05mg/kg bd (levels 6-12ng/ml)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Serious Adverse Events</title>
          <units>serious adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Baseline Glomerular Filtration Rate</title>
        <time_frame>3 years</time_frame>
        <population>data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Prednisolone</title>
            <description>prednisolone tablets&#xD;
prednisolone: Prednisolone 1mg/kg maximum 60mg od</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus</title>
            <description>tacrolimus tablets&#xD;
tacrolimus: tacrolimus0.05mg/kg bd (levels 6-12ng/ml)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Baseline Glomerular Filtration Rate</title>
          <population>data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Prednisolone</title>
          <description>prednisolone tablets&#xD;
prednisolone: Prednisolone 1mg/kg maximum 60mg od</description>
        </group>
        <group group_id="E2">
          <title>Tacrolimus</title>
          <description>tacrolimus tablets&#xD;
tacrolimus: tacrolimus0.05mg/kg bd (levels 6-12ng/ml)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diverticualr disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>fracture radius</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>respiratory infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash and diarhoaea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>various non serious</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="25"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Megan Griffith</name_or_title>
      <organization>Imperial College NHS Trust</organization>
      <phone>02033137309</phone>
      <email>m.e.griffith@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

